In clinics, disease diagnosis is typically done by observing symptoms or using paper-strip antibody tests. However, these methods often have poor sensitivity compared to DNA diagnostics such as PCR. But PCR are not often used because of cost and the slow turnaround time (several days).
mFluiDx is a UC Berkeley startup developing Gates Foundation funded low-cost microfluidic diagnostic technologies capable of on-site multi-target DNA detection of viral and bacterial infections, with <15 min fully automated operation and ~50X lower cost than PCR setups. We aim to create assays that can be deployed in decentralized settings, are as simple and cheap as paper tests, yet have DNA level sensitivity for onsite diagnosis.
mFluiDx supported by NSF, NIH SBIR grants, it has been selected as top 20 startups at TechCrunch (pool of 9000 startups), selected to join Indiebio Accelerator, selected to join QB3 incubator, CITRIS Foundry, and has completed Steve Blank’s lean-launch training, interviewing...
In clinics, disease diagnosis is typically done by observing symptoms or using paper-strip antibody tests. However, these methods often have poor sensitivity compared to DNA diagnostics such as PCR. But PCR are not often used because of cost and the slow turnaround time (several days).
mFluiDx is a UC Berkeley startup developing Gates Foundation funded low-cost microfluidic diagnostic technologies capable of on-site multi-target DNA detection of viral and bacterial infections, with <15 min fully automated operation and ~50X lower cost than PCR setups. We aim to create assays that can be deployed in decentralized settings, are as simple and cheap as paper tests, yet have DNA level sensitivity for onsite diagnosis.
mFluiDx supported by NSF, NIH SBIR grants, it has been selected as top 20 startups at TechCrunch (pool of 9000 startups), selected to join Indiebio Accelerator, selected to join QB3 incubator, CITRIS Foundry, and has completed Steve Blank’s lean-launch training, interviewing 200+ experts in the customer ecosystem, and confirmed product market fit.
More information

Employees

Charlie Yeh
Admin
Charlie Yeh CEO Berkeley Bioengineering PhD 15'. I am the lead inventor of the SIMPLE microfluidic technology, with four patents filed.
Todd Wallis
Admin
Todd Wallis Engineer